NewAmsterdam Pharma Company N.V.
NAMS
$36.47
-$3.98-9.84%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 542.88% | -76.68% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 542.88% | -76.68% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 542.88% | -76.68% | |||
| SG&A Expenses | 0.41% | 28.65% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -23.81% | 28.40% | |||
| Operating Income | 48.30% | -59.44% | |||
| Income Before Tax | 56.07% | 57.12% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 56.07% | 57.12% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 56.07% | 57.12% | |||
| EBIT | 48.30% | -59.44% | |||
| EBITDA | 48.33% | -59.51% | |||
| EPS Basic | 56.96% | 63.28% | |||
| Normalized Basic EPS | 60.93% | 56.27% | |||
| EPS Diluted | 56.96% | 63.28% | |||
| Normalized Diluted EPS | 60.93% | 56.27% | |||
| Average Basic Shares Outstanding | 2.09% | 16.79% | |||
| Average Diluted Shares Outstanding | 2.09% | 16.79% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||